CIBC Private Wealth Group LLC Lowers Stake in Abbott Laboratories $ABT

CIBC Private Wealth Group LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,016,091 shares of the healthcare product maker’s stock after selling 102,121 shares during the period. Abbott Laboratories makes up about 0.9% of CIBC Private Wealth Group LLC’s portfolio, making the stock its 17th largest holding. CIBC Private Wealth Group LLC’s holdings in Abbott Laboratories were worth $537,915,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Cloud Capital Management LLC purchased a new position in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC raised its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the period. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $108.41 on Thursday. The company’s 50-day moving average is $113.54 and its two-hundred day moving average is $123.39. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm has a market capitalization of $188.81 billion, a price-to-earnings ratio of 29.14, a PEG ratio of 1.76 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Buying and Selling

In related news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. Citigroup cut their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Daiwa Securities Group lowered their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.